Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for single-administration therapies. In a report published today, OHE authors present key considerations for developing early access schemes for single-administration therapies.
In a commentary piece recently published in Applied Health Economics and Health Policy, OHE authors discuss how the misalignment in interpretations of the term ‘unmet medical need’ by different stakeholders has led to insufficient incentives for development in areas with urgent, genuine need, and propose a new framework for developing a more consistent understanding of UMN that will increase innovation.
The HTAi 2021 Annual Meeting (‘Innovation Through HTA’) will take place virtually from Saturday, June 19, to Wednesday, June 23, 2021. A number of the team from OHE will be in attendance to present their research.
Our new paper explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there is much that can and should be done to improve the evidence base to inform the allocation of public sector budgets across portfolios. We propose a pragmatic approach to measure and value disparate public sector outputs in a commensurate manner.
In a recently published report, we explore the financial sustainability of gene therapies and highlight the factors that are likely to influence the financial sustainability of this important medical technology.